Insulin lispro and Technosphere insulin (Afrezza) represent two distinct delivery approaches for rapid-acting insulin. Lispro is a parenteral rapid-acting analogue with well-characterized PK; Technosphere insulin is a pulmonary-delivered insulin with ultra-rapid absorption and elimination. Their comparison illustrates the pharmacokinetic trade-offs between injectable and inhaled insulin delivery.
- Sequence: Human insulin with LysB28, ProB29 swap
- Modifications: Reversal of B28-B29 (Lys-Pro → Pro-Lys)
- MW: 5,808 Da
- Charge at pH 7.4: −1
- Formulation: Aqueous solution, 100 U/mL or 200 U/mL
- Route: Subcutaneous injection
- FDA-approved: 1996
- Composition: Recombinant human insulin adsorbed onto Technosphere microparticles (fumaryl diketopiperazine)
- Microparticle size: 2–3 µm (optimized for deep lung deposition)
- Insulin load: ~1,100 U per cartridge
- Route: Pulmonary inhalation
- FDA-approved: 2014
| Parameter | Insulin Lispro (SC) | Technosphere (Inhaled) |
|---|
| Onset | 10–15 minutes | 5–10 minutes |
| T_max | 30–90 minutes | 12–15 minutes |
| Duration | 3–5 hours | 1.5–3 hours |
| Bioavailability | ~60% (SC) | ~10–15% (inhaled) |
| Peak concentration | 20–50 mU/L | 30–70 mU/L |
| Insulin | Onset | T_max | Duration |
|---|
| Lispro (Humalog) | 10–15 min | 30–90 min | 3–5 h |
| Aspart (NovoRapid) | 10–15 min | 30–90 min | 3–5 h |
| Glulisine (Apidra) | 10–15 min | 30–90 min | 3–5 h |
| Technosphere (Afrezza) | 5–10 min | 12–15 min | 1.5–3 h |
| Faster aspart (Fiasp) | 5–10 min | 15–30 min | 3–5 h |
- Deposition: 2–3 µm particles deposit in bronchioles (generation 14–17)
- Rapid dissolution: Technosphere dissolves in lung fluid
- Insulin absorption: Insulin crosses alveolar epithelium
- Systemic circulation: Enters pulmonary veins → left heart → systemic
- Bypasses first-pass: No hepatic first-pass metabolism
- Rapid elimination: Insulin rapidly cleared from lung
| Parameter | Insulin Lispro | Technosphere |
|---|
| PPG reduction (1 hr) | 80–120 mg/dL | 100–150 mg/dL |
| PPG reduction (2 hr) | 100–150 mg/dL | 60–100 mg/dL |
| Time to peak glucose control | 60–90 min | 15–30 min |
| Duration of control | 3–5 hours | 1.5–3 hours |
| Match to meal | Requires timing | Matches rapid absorption |
| Parameter | Insulin Lispro | Technosphere |
|---|
| HbA1c reduction | −0.8 to −1.2% | −0.6 to −1.0% |
| Non-inferior to lispro | — | Yes (non-inferior) |
| Hypoglycemia (overall) | 20–30% | 20–30% |
| Nocturnal hypoglycemia | 5–10% | 3–7% |
- Dosing unit: 1 unit = 1 unit of insulin
- Timing: 15 minutes before meals (or with meals)
- Dose adjustment: Based on PPG, carb ratio, correction factor
- Pen device: Humalog KwikPen, Tempo Pen
- Vial: 100 U/mL, 200 U/mL
- Storage: Room temperature (28 days open), refrigerated (unopened)
- Dosing unit: 4, 8, or 12 units per cartridge (not equivalent to SC units)
- Timing: Within 20 minutes before meals
- Dose adjustment: Based on PPG; ~50% of SC rapid-acting dose
- Inhaler device: Dreamboat inhaler (reusable)
- Cartridge: Single-use, pre-loaded
- Storage: Refrigerated (unopened), room temperature (open)
| SC Lispro Dose | Technosphere Dose | Conversion Ratio |
|---|
| 4 U | 4 U (1 cartridge) | 1:1 |
| 8 U | 8 U (1 cartridge) | 1:1 |
| 12 U | 12 U (1 cartridge) | 1:1 |
| 16 U | 8 U × 2 cartridges | 2:1 |
| 20 U | 12 U + 8 U | ~1.5:1 |
| >24 U | Multiple cartridges | Variable |
| Adverse Effect | Frequency | Severity |
|---|
| Injection site reaction | 5–10% | Mild |
| Hypoglycemia | 20–30% | Moderate |
| Weight gain | 1–3 kg | Mild |
| Lipodystrophy | Rare | Local |
| Allergic reaction | Very rare | Severe |
| Adverse Effect | Frequency | Severity |
|---|
| Cough | 30–50% | Mild–Moderate |
| Hypoglycemia | 20–30% | Moderate |
| Throat irritation | 10–20% | Mild |
| Weight gain | 0.5–2 kg | Mild |
| Bronchospasm | 1–3% | Moderate |
| Decline in FEV1 | 5–10% | Moderate |
| Parameter | Technosphere | Monitoring |
|---|
| FEV1 decline | ~30–50 mL (first 6 months) | Spirometry q3 months |
| Cough | 30–50% (usually transient) | Symptom monitoring |
| Bronchospasm | 1–3% | FEV1, symptoms |
| Lung function stability | Generally stable after initial decline | Annual spirometry |
| Contraindication | Asthma, COPD, smoking | Screening |
- Hypoglycemia
- Hypersensitivity to lispro or excipients
- Chronic lung disease (asthma, COPD)
- Current smoking or recently quit (<6 months)
- FEV1 <70% predicted
- Hypersensitivity to fumaryl diketopiperazine
- DKA
- Children <18 years
- Basal-bolus regimen established
- Insulin pump therapy needed
- Precise dose titration required
- Lung disease present
- Smoking history
- Pediatric patient
- Needle phobia or injection resistance
- Postprandial glucose spike (rapid absorption)
- Desire to avoid injection (cosmetic/comfort)
- No lung disease
- Non-smoker
- Adequate pulmonary function (FEV1 >70%)
| Parameter | Insulin Lispro | Technosphere |
|---|
| Monthly cost (US) | $200–400 | $300–500 |
| Inhaler cost | N/A | $50–100 (reusable) |
| Cartridge cost | N/A | ~$10–15 each |
| Insurance coverage | Widely covered | Expanding coverage |
| Copay assistance | Manufacturer programs | Manufacturer programs |
Insulin lispro and Technosphere insulin both provide rapid-acting insulin coverage, but through fundamentally different delivery mechanisms. Lispro offers well-characterized PK, flexible dosing, and broad clinical applicability through SC injection. Technosphere provides ultra-rapid absorption (T_max 12–15 min) and needle-free delivery, but with lower bioavailability (10–15%), cough (30–50%), FEV1 concerns, and lung disease contraindications. Technosphere is best suited for patients with needle phobia, rapid postprandial spikes, and intact pulmonary function. Lispro remains the standard for basal-bolus regimens and pump therapy.
